Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial

By afschroeder • September 20, 2026

Neely J, Yao J, Kudo M, Finn RS, Sangro B, Melero I, El-Khoueiry AB, Yau T, Harding JJ, Rosmorduc O, Tschaika M, Novosiadly R, Cruz A, Kelley RK. Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial. JHEP Rep. 2026 Sep 19:102038. doi: 10.1016/j.jhepr.2026.102038. Epub ahead of print. PMID: 42762856.

Tags: Biomarker, Cardiology/Epi, Checkpoint Inhibitor, Hepatocellular carcinoma, nivolumab, Publications

Artificial intelligence-derived splenic response in cardiac positron emission tomography is associated with major adverse cardiovascular events: a multi-site study

Ramirez G, Dharmavaram NL, Shanbhag A, Miller RJH, Kavanagh PB, Yi J, Lemley M, Builoff V, Marcinkiewicz A, Dey D, Hainer J, Wopperer S, Knight[...]

Deep learning-enabled screening of chronic kidney disease from echocardiography

Yuan V, Ieki H, Sandhu A, Nguyen LH, Cheng PP, Chang ST, Ambrosy AP, Kwan AC, Go AS, Cheng S, Ouyang D. Deep learning-enabled screening[...]

Uric acid to high-density lipoprotein cholesterol ratio and cardiovascular disease: a novel biomarker or a passing trend?

Bazrafshan M, Shamsa K, Namazee M, Kamali M, Bazrafshan Drissi H, Hooshanginezhad Z. Uric acid to high-density lipoprotein cholesterol ratio and cardiovascular disease: a novel[...]